Sarepta Therapeutics Inc

자세한 내용은 Sarepta Therapeutics Inc 회사

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

회사 정보

종목 코드 SRPT

회사 이름Sarepta Therapeutics Inc

상장일Jun 04, 1997

설립일2013

CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.

직원 수1372

유형Ordinary Share

회계 연도 종료Jun 04

주소215 1st St Ste 415

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02142-1213

전화16172744000

웹사이트https://www.sarepta.com/

종목 코드 SRPT

상장일Jun 04, 1997

설립일2013

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Richard J. (Rick) Barry

Independent Director

3.21M

+1.02%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

President, Chief Executive Officer, Director

390.31K

--

Dr. Louise Rodino-Klapac, Ph.D.

Executive Vice President, Chief Scientific Officer, Head of R&D

57.60K

+21.66%

Mr. Ian Michael Estepan

Chief Financial Officer, Executive Vice President

45.59K

+0.22%

Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.

Independent Director

22.84K

-2.30%

Mr. Dallan Murray

Executive Vice President, Chief Customer Officer

21.18K

-44.29%

Cristin Rothfuss

Executive Vice President, General Counsel, Corporate Secretary

19.15K

+38.59%

Mr. Bilal Arif

Executive Vice President , Chief Technical Operations Officer

16.42K

-16.76%

Ms. Deirdre Connelly

Independent Director

--

Dr. Claude Nicaise, M.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Richard J. (Rick) Barry

Independent Director

3.21M

+1.02%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

President, Chief Executive Officer, Director

390.31K

--

Dr. Louise Rodino-Klapac, Ph.D.

Executive Vice President, Chief Scientific Officer, Head of R&D

57.60K

+21.66%

Mr. Ian Michael Estepan

Chief Financial Officer, Executive Vice President

45.59K

+0.22%

Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.

Independent Director

22.84K

-2.30%

Mr. Dallan Murray

Executive Vice President, Chief Customer Officer

21.18K

-44.29%

수익 분석

통화: USD마지막 업데이트: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

사업별USD

이름

수익

비율

PMO Products

967.17M

50.85%

ELEVIDYS

820.79M

43.15%

collaboration and other

114.02M

5.99%

지역별USD

이름

수익

비율

United States

1.64B

86.11%

Rest of World

150.25M

7.90%

사업별

지역별

사업별USD

이름

수익

비율

PMO Products

967.17M

50.85%

ELEVIDYS

820.79M

43.15%

collaboration and other

114.02M

5.99%

주식 보유 통계

마지막 업데이트: Mon, May 19

주주

주주 유형

주주

비율

Capital International Investors

9.22%

The Vanguard Group, Inc.

9.17%

BlackRock Institutional Trust Company, N.A.

9.06%

Capital Research Global Investors

6.17%

State Street Global Advisors (US)

4.14%

Other

62.25%

주주

비율

Capital International Investors

9.22%

The Vanguard Group, Inc.

9.17%

BlackRock Institutional Trust Company, N.A.

9.06%

Capital Research Global Investors

6.17%

State Street Global Advisors (US)

4.14%

Other

62.25%

주주 유형

주주

비율

Investment Advisor

42.91%

Investment Advisor/Hedge Fund

37.22%

Hedge Fund

9.45%

Individual Investor

4.42%

Research Firm

3.31%

Bank and Trust

1.10%

Pension Fund

1.10%

Sovereign Wealth Fund

1.09%

Venture Capital

0.33%

기관 주식 보유

마지막 업데이트: Mon, Jan 20

보고 기간

기관 수

보유 주식

비율

변동

2025Q1

1045

100.62M

102.55%

-5.73M

2024Q4

1057

102.62M

105.91%

-1.51M

2024Q3

1027

96.14M

100.83%

-6.90M

2024Q2

997

94.21M

99.66%

-1.44M

2024Q1

932

88.31M

94.10%

-6.68M

2023Q4

926

87.42M

93.47%

-6.42M

2023Q3

916

88.86M

95.27%

-4.43M

2023Q2

931

87.46M

93.91%

-4.38M

2023Q1

946

86.41M

92.84%

-2.26M

2022Q4

996

84.01M

95.72%

-10.12M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Capital International Investors

8.70M

8.96%

+2.44M

+38.95%

Dec 31, 2024

The Vanguard Group, Inc.

9.07M

9.34%

+117.52K

+1.31%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

8.94M

9.21%

+162.26K

+1.85%

Dec 31, 2024

Capital Research Global Investors

5.93M

6.11%

+49.00

+0.00%

Feb 28, 2025

State Street Global Advisors (US)

4.07M

4.19%

-200.90K

-4.70%

Dec 31, 2024

Janus Henderson Investors

4.33M

4.46%

-30.19K

-0.69%

Dec 31, 2024

Barry (Richard J)

3.18M

3.28%

+2.38K

+0.07%

Mar 10, 2025

Avoro Capital Advisors LLC

2.56M

2.63%

--

Dec 31, 2024

Wellington Management Company, LLP

2.07M

2.13%

-657.84K

-24.13%

Dec 31, 2024

Farallon Capital Management, L.L.C.

2.87M

2.95%

+285.10K

+11.05%

Dec 31, 2024

20.940USD

Sarepta Therapeutics Inc

20.940

개요

회사